Haemophilia, state of the art and new therapeutic opportunities, a regulatory perspective

por Tomeo, Francesca, Mariz, Segundo, Brunetta, Angelo Loris, Stoyanova‐Beninska, Violeta, Penttila, Karri, Magrelli, Armando
Publicado 2021

Are products with an orphan designation for oncology indications different from products for other rare indications? A retrospective analysis of European orphan designations grante...

por Pauwels, Kim, Huys, Isabelle, Casteels, Minne, Larsson, Kristina, Voltz, Caroline, Penttila, Karri, Morel, Thomas, Simoens, Steven
Publicado 2017

The European Medicines Agency Review of Crizanlizumab for the Prevention of Recurrent Vaso-Occlusive Crises in Patients With Sickle Cell Disease

por Delgado, Julio, Voltz, Caroline, Stain, Milena, Lapveteläinen, Tuomo, Urach, Susanne, Lähteenvuo, Johanna, Penttilä, Karri, Gisselbrecht, Christian, Enzmann, Harald, Pignatti, Francesco
Publicado 2021

CD34(+) Cell Mobilization, Autograft Cellular Composition and Outcome in Mantle Cell Lymphoma Patients

por Turunen, Antti Samuli, Kuittinen, Outi, Kuitunen, Hanne, Vasala, Kaija, Penttilä, Karri, Harmanen, Minna, Keskinen, Leena, Mäntymaa, Pentti, Pelkonen, Jukka, Varmavuo, Ville, Jantunen, Esa, Partanen, Anu
Publicado 2023

European Medicines Agency review of ixazomib (Ninlaro) for the treatment of adult patients with multiple myeloma who have received at least one prior therapy

por Tzogani, Kyriaki, Florez, Beatriz, Markey, Greg, Caleno, Mariapaola, Olimpieri, Odoardo Maria, Melchiorri, Daniela, Hovgaard, Doris Johanna, Sarac, Sinan Bardakci, Penttilä, Karri, Lapveteläinen, Tuomo, Salmonson, Tomas, Bergh, Jonas, Gisselbrecht, Christian, Pignatti, Francesco
Publicado 2019